secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jaguar Health, Inc. (JAGX)
CIK:        0001585608
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0000950170-25-038861
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jaguar Health shareholders OK reverse stock split; crofelemer POC data and FDA meeting expected Q2 2025
--------------------------------------------------------------------------------

- Shareholders voted 5,281,329 for and 1,377,494 against the reverse stock split (ratio 1:15 to 1:40); board to set exact ratio by March 2026.
- First proof-of-concept investigator-initiated trial results for crofelemer in SBS-IF and MVID are expected in Q2 2025.
- Company expects FDA meeting in Q2 2025 to discuss Phase 3 OnTarget breast cancer subgroup results and potential approval path.
- Adjournment proposal also approved with 5,423,671 for and 1,163,222 against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585608/000095017025038861/0000950170-25-038861-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585608/000095017025038861/jagx-20250313.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-038861

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer